



BC Centre for Disease Control
Provincial Health Services Authority

Immunization Programs and Vaccine Preventable Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: April 4, 2023

Administrative Circular: 2023:11

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 1 – Immunization Schedules, Part 2 – Immunization of Special Populations &
Part 4 – Biological Products**

Part 1- Immunization Schedules

3.1 Minimum Intervals Between Vaccine Doses Table

- 'Grade 6 program' has been removed from Hepatitis B Recombivax HB® and Engerix®-B 2-dose series. Corresponding footnote E has been revised to indicate "This schedule applies only for those 11-15 years of age; however, a minimum age of 10 years and 8 months may be used for catch-up of grade 6 students for operational purposes."
- Cervarix® has been removed from the HPV series.
- Minimum age for the pneumococcal conjugate 3-dose series has been revised from 8 weeks to 6 weeks in alignment with the Canadian Immunization Guide.

**Please remove pages number: 14 & 15 dated October 2020
Please add new page number: 14 & 15 dated April 2023**

Part 2- Immunization of Special Populations

Specific Immunocompromising Conditions

Chronic Kidney Disease

- The version date for the *BC Renal Agency Hepatitis B Guidelines* has been revised to March 2022.
- Footnote B within the *Hepatitis B Vaccine Program for Chronic Kidney Disease Clients* dosing table has been revised to clarify that the adult presentation of ENGERIX®-B (20 mcg/1 mL) or RECOMBIVAX HB® (10 mcg/1 mL) can be used for individuals \leq 19 years of age.

**Please remove page numbers: 1-3 dated October 2019
Please add new page numbers: 1-3 dated April 2023**

Page 1 of 3

Part 4 – Biological Products

Hepatitis Vaccines

Hepatitis B Vaccine: ENGERIX®-B

- Indications under DOSES AND SCHEDULE have been reorganized for clarity, and 'routine grade 6 program' has been removed.
- A new footnote associated with the schedule for 'Adolescents 11-15 years of age (inclusive)' has been added that states "A minimum age of 10 years and 8 months may be used for catch-up of grade 6 students for operational purposes."
- PRODUCT COMPONENTS have been updated based on the most recent product monograph.

Please remove page numbers: 1 & 2 dated January 2018

Please add new page numbers: 1 & 2 dated April 2023

Hepatitis B Vaccine: RECOMBIVAX HB®

- Indications under DOSES AND SCHEDULE have been reorganized for clarity, and 'routine grade 6 program' has been removed.
- A new footnote associated with the schedule for 'Adolescents 11-15 years of age (inclusive)' has been added that states "A minimum age of 10 years and 8 months may be used for catch-up of grade 6 students for operational purposes."

Please remove page numbers: 1 & 2 dated January 2018

Please add new page numbers: 1 & 2 dated April 2023

Hepatitis B Vaccine Higher Dose Schedule

- The concentrations of ENGERIX®-B (20 mcg/1 mL) and RECOMBIVAX HB® (10 mcg/1 mL) have been included in the table heading for clarity of product selection.
- Footnote D has been revised to clarify that the RECOMBIVAX HB® Dialysis Formulation (40 mcg/1 mL) should *not* be used, with the exception of HSCT recipients and kidney transplant candidates and recipients 20 years of age and older who should receive 1 mL of the RECOMBIVAX HB® Dialysis Formulation (40 mcg/1 mL).
- A new footnote has been added to clarify that the adult presentation of ENGERIX®-B (20 mcg/1 mL) or RECOMBIVAX HB® (10 mcg/1 mL) can be used for individuals ≤ 19 years of age.

Please remove page number: 1 dated October 2019

Please add new page number: 1 dated April 2023

Hepatitis B Vaccine Program for Chronic Kidney Disease Clients

- The version date for the BC Renal Agency Hepatitis B Guidelines has been revised to March 2022.
- Footnote B has been revised to clarify that the adult presentation of ENGERIX®-B (20 mcg/1 mL) or RECOMBIVAX HB® (10 mcg/1 mL) can be used for individuals ≤ 19 years of age.

Please remove page number: 1 dated October 2019
Please add new page number: 1 dated April 2023

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease,
Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division